Alerts will be sent to your verified email
Verify Email
WINDLAS
|
Windlas Biotech
|
Amrutanjan Healthcar
|
Beta Drugs
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
10.64 % | 14.67 % | 21.73 % |
|
5yr average Equity Multiplier
|
1.39 | 1.41 | 1.75 |
|
5yr Average Asset Turnover Ratio
|
1.07 | 1.22 | 1.04 |
|
5yr Avg Net Profit Margin
|
7.49 % | 8.57 % | 11.97 % |
|
Price to Book
|
3.92 | 6.32 | 0.0 |
|
P/E
|
30.45 | 37.83 | 43.21 |
|
5yr Avg Cash Conversion Cycle
|
-12.87 Days | 21.59 Days | 15.7 Days |
|
Inventory Days
|
39.91 Days | 23.18 Days | 43.83 Days |
|
Days Receivable
|
72.81 Days | 51.48 Days | 87.61 Days |
|
Days Payable
|
93.99 Days | 49.13 Days | 113.94 Days |
|
5yr Average Interest Coverage Ratio
|
42.87 | 27.21 | 13.71 |
|
5yr Avg ROCE
|
16.39 % | 24.07 % | 27.85 % |
|
5yr Avg Operating Profit Margin
|
12.11 % | 14.15 % | 21.58 % |
|
5 yr average Debt to Equity
|
0.05 | 0.12 | 0.23 |
|
5yr CAGR Net Profit
|
30.97 % | 16.38 % | 31.07 % |
|
5yr Average Return on Assets
|
7.71 % | 10.59 % | 12.53 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
62.34 % | 46.52 % | 66.73 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
2.39 % | -3.5 % | 0.02 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-5.1 % | 1.61 % | 0.0 |
|
Windlas Biotech
|
Amrutanjan Healthcar
|
Beta Drugs
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
|
Segment Wise Break-Up
|
Segment Wise Break-Up
|
-
|
-
|